Phase 2 trial demonstrates significant reduction of S. aureus colonization with probiotic use

author
3 minutes, 28 seconds Read

A new NIH study sheds light on the gut’s role in colonizing staph.

In a Phase 2 clinical study, a promising method to control Staphylococcus Aureus bacteria colonization was found to be safe and highly efficient. The Lancet Microbe reported that the new study found that Bacillus subtilis, a probiotic, significantly reduced S. The probiotic Bacillus subtilis reduced S. aureus colonization among trial participants, without harming gut microbiota. This includes beneficial bacteria. Researchers at the National Institutes of Health conducted the research under the leadership of Michael Otto, Ph.D. a senior investigator with the National Institute of Allergy and Infectious Diseases.

Methicillin-resistant S. Many people are familiar with MRSA or S. aureus as a serious cause of disease. S. aureus is a lesser-known pathogen. S. aureus can live in the nose, the body and the gut, without harming anyone. If the skin barrier breaks or the immune system becomes compromised, the colonizing bacteria may cause serious infections of the skin, bones, lungs, and blood.

S. aureus infections can be prevented by “decolonizing” the body. This is gaining more attention as antibiotic resistance limits treatment options. The spread of antibiotic resistant has limited treatment options. Some decolonization methods are controversial, as they require high doses of antibiotics. This raises concerns about the damage to microbiota or the development of resistance. It appears so far that nasal S. Topical antibiotics can be used to treat S. aureus colonization without causing too much damage. However, bacteria can quickly recolonize the nose after entering the stomach.

Probiotics or digestive supplements that contain live microorganisms can be used to replace antibiotics. The probiotic Bacillus, which is taken orally in the form of spores and can survive stomach passage to grow temporarily in the intestine, is particularly promising. Dr. Otto and his team discovered an S. Dr. Otto’s group discovered in previous studies that S. Aureus can grow in the gut. The researchers also discovered that fengycins (Bacillus lipopeptides), which are a mixture of lipid and peptide, inhibit the S. The S. aureus sense system is prevented from working, eliminating the bacteria.

MRSA (yellow), being ingested (purplish-blue) by neutrophils.NIAID

The research team in Thailand tested this method on people in a clinical trial. The researchers recruited 115 healthy individuals, who were all naturally colonized with S. aureus. A group of 65 people received B. The control group, 60 people, received a placebo. Researchers evaluated participants’ S. After four weeks, researchers evaluated the participants’ S. The control group showed no change, but the probiotic group saw a reduction of 96.8% in S. aureus in the stool, and a reduction of 65.4% in the nose.

The probiotics we use do not “kill” S. aureus, but they specifically and strongly reduce its ability to colonize,” Dr. Otto said. “The probiotic we use does not ‘kill’ S. “We believe we can target ‘bad’ S. “We think we can target the ‘bad’ S.

Researchers also found that S. aureus bacteria levels in the gut far exceeded S. Researchers also found that levels of S. Aureus in nose has been the subject of research on staph prevention for decades. This discovery adds to the importance of S. Aureus in the gut.

Dr. Otto stated that “Intestinal S. Aureus colonization was evident for decades but it was mostly ignored by researchers as antibiotics were not viable targets.” “Our results suggest that there is a safe and effective way to reduce the number of colonizing S. Our results suggest a way to safely and effectively reduce the total number of colonizing S. “Aureus colonization of human body.”

Researchers plan to continue testing probiotics in a longer and larger trial. The researchers note that although their approach may not be as effective as antibiotics in treating infections, it can still be used over a long period of time because the probiotic used in the trial is not harmful. The study collaborators from Thailand are the Rajamangala University of Technology Srivijaya and Prince of Songkla University.

,

Similar Posts